|
| | Brivanib alaninate Basic information |
| | Brivanib alaninate Chemical Properties |
| density | 1.42±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | ≥22.05 mg/mL in DMSO; insoluble in H2O; ≥10.03 mg/mL in EtOH | | form | Yellow powder. | | pka | 16.08±0.30(Predicted) |
| | Brivanib alaninate Usage And Synthesis |
| Uses | A novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor. | | Uses | BMS-582664 is an oral VEGFR/FGFR inhibitor for VEGFR2, Flk1, VEGFR1 and FGFR1 with IC50 of 25 nM, 89 nM, 380 nM and 148 nM, respectively. | | Definition | ChEBI: Brivanib alaninate is a carboxylic ester resulting from the formal condensation of the carboxy group of L-alanine with the hydroxy group of brivanib. It is a prodrug of brivanib (BMS-540215), a potent oral dual inhibitor of VEGFR-2 and FGFR-1 (IC50 of 25 nM and 148 nM, respectively) and was in development for the treatment of hepatocellular and colon carcinomas. It has a role as an antineoplastic agent, an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor, a prodrug, an apoptosis inducer, a fibroblast growth factor receptor antagonist and an angiogenesis inhibitor. It is a pyrrolotriazine, an aromatic ether, a fluoroindole, a diether, a carboxylic ester and a L-alanine derivative. It is functionally related to a brivanib. | | target | VEGFR2 |
| | Brivanib alaninate Preparation Products And Raw materials |
|
